If it looks cloudy or contains particles, do not use it
Wegovy (semaglutide injection) received FDA approval in June 2021 for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidemia
Finally, while the timing of observed changes aligns closely with the formulary update, this analysis does not establish causality, and other factors such as regional policies, supply dynamics, or provider preferences may have contributed
This can then be continued when semaglutide is stopped to help prevent weight gain
However, this average can fluctuate depending on various factors, including how strictly the individual follows their diet, their exercise habits, and their overall metabolism
If you are preparing multiple dose levels for a titration schedule , color-coding with different marker colors prevents dangerous mix-ups